Literature DB >> 22930275

Physical exercise reduces cardiac defects in type 2 spinal muscular atrophy-like mice.

Olivier Biondi1, Philippe Lopes, Céline Desseille, Julien Branchu, Farah Chali, Amina Ben Salah, Claude Pariset, Christophe Chanoine, Frédéric Charbonnier.   

Abstract

Spinal muscular atrophy (SMA), the leading genetic cause of death in infants worldwide, is due to the misexpression of the survival of motor neuron protein, causing death of motor neurons. Several clinical symptoms suggested that, in addition to motor neurons, the autonomic nervous systems could be implicated in the cardiac function alterations observed in patienst with SMA. These alterations were also found in a severe SMA mouse model, including bradycardia and a reduction of sympathetic innervation, both associated with autonomic imbalance. In the present study, we investigate the extent of autonomic dysfunction and the effects of a running-based exercise on the altered cardiorespiratory function in type 2 SMA-like mice. We observed that the SMA induced: (1) a dramatic alteration of intrinsic cardiac conduction associated with bradycardia; (2) a severe cardiomyopathy associated with extensive ventricular fibrosis; and (3) a delay in cardiac muscle maturation associated with contractile protein expression defects. Furthermore, our data indicate that the sympathetic system is not only functioning, but also likely contributes to alleviate the bradycardia and the arrhythmia in SMA-like mice. Moreover, physical exercise provides many benefits, including the reduction of cardiac protein expression defect, the reduction of fibrosis, the increase in cardiac electrical conduction velocity, and the drastic reduction in bradycardia and arrhythmias resulting in the partial restoration of the cardiac function in these mice. Thus, modulating the cardiorespiratory function in SMA could represent a new target for improving supportive care and for developing new pharmacological and non-pharmacological interventions that would most certainly include physical exercise.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22930275      PMCID: PMC3528999          DOI: 10.1113/jphysiol.2012.238196

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  55 in total

1.  Analysis of myosin heavy chain functionality in the heart.

Authors:  Maike Krenz; Atsushi Sanbe; Florence Bouyer-Dalloz; James Gulick; Raisa Klevitsky; Timothy E Hewett; Hanna E Osinska; John N Lorenz; Christine Brosseau; Andrea Federico; Norman R Alpert; David M Warshaw; M Benjamin Perryman; Steve M Helmke; Jeffrey Robbins
Journal:  J Biol Chem       Date:  2003-03-06       Impact factor: 5.157

2.  Exercise ECGs in angina. Which "angiographic positives" will die from heart disease?

Authors:  G H Hall
Journal:  BMJ       Date:  2008-12-24

3.  Reporting ethical matters in the Journal of Physiology: standards and advice.

Authors:  Gordon B Drummond
Journal:  J Physiol       Date:  2009-02-15       Impact factor: 5.182

4.  Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice.

Authors:  C I Berul; M E Christe; M J Aronovitz; C E Seidman; J G Seidman; M E Mendelsohn
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 5.  Baroreflexes and the failing human heart.

Authors:  D L Eckberg
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

6.  Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart.

Authors:  W K Jones; I L Grupp; T Doetschman; G Grupp; H Osinska; T E Hewett; G Boivin; J Gulick; W A Ng; J Robbins
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

7.  Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery.

Authors:  Adam K Bevan; Kirk R Hutchinson; Kevin D Foust; Lyndsey Braun; Vicki L McGovern; Leah Schmelzer; Jennifer G Ward; Jeffrey C Petruska; Pamela A Lucchesi; Arthur H M Burghes; Brian K Kaspar
Journal:  Hum Mol Genet       Date:  2010-07-16       Impact factor: 6.150

8.  Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy.

Authors:  Magali Michaud; Thomas Arnoux; Serena Bielli; Estelle Durand; Yann Rotrou; Sibylle Jablonka; Fabrice Robert; Marc Giraudon-Paoli; Markus Riessland; Marie-Geneviève Mattei; Emile Andriambeloson; Brunhilde Wirth; Michael Sendtner; Jorge Gallego; Rebecca M Pruss; Thierry Bordet
Journal:  Neurobiol Dis       Date:  2010-01-18       Impact factor: 5.996

9.  Vascular perfusion abnormalities in infants with spinal muscular atrophy.

Authors:  Alexandra prufer de Queiroz Campos Araujo; Mario Araujo; Kathryn J Swoboda
Journal:  J Pediatr       Date:  2009-08       Impact factor: 4.406

10.  The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation.

Authors:  Rebeca Martínez-Hernández; Carolina Soler-Botija; Eva Also; Laura Alias; Lidia Caselles; Ignasi Gich; Sara Bernal; Eduardo F Tizzano
Journal:  J Neuropathol Exp Neurol       Date:  2009-05       Impact factor: 3.685

View more
  11 in total

1.  The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice.

Authors:  Matthew E R Butchbach; Jasbir Singh; Mark E Gurney; Arthur H M Burghes
Journal:  Exp Neurol       Date:  2014-03-25       Impact factor: 5.330

Review 2.  Spinal muscular atrophy: an update on therapeutic progress.

Authors:  Joonbae Seo; Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Biochim Biophys Acta       Date:  2013-08-27

3.  The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.

Authors:  Constantin d'Ydewalle; Daniel M Ramos; Noah J Pyles; Shi-Yan Ng; Mariusz Gorz; Celeste M Pilato; Karen Ling; Lingling Kong; Amanda J Ward; Lee L Rubin; Frank Rigo; C Frank Bennett; Charlotte J Sumner
Journal:  Neuron       Date:  2016-12-22       Impact factor: 17.173

4.  Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy.

Authors:  Matthew E R Butchbach; Casey J Lumpkin; Ashlee W Harris; Luciano Saieva; Jonathan D Edwards; Eileen Workman; Louise R Simard; Livio Pellizzoni; Arthur H M Burghes
Journal:  Exp Neurol       Date:  2016-02-15       Impact factor: 5.330

Review 5.  Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications?

Authors:  Chiara Simone; Agnese Ramirez; Monica Bucchia; Paola Rinchetti; Hardy Rideout; Dimitra Papadimitriou; Diane B Re; Stefania Corti
Journal:  Cell Mol Life Sci       Date:  2015-12-18       Impact factor: 9.261

Review 6.  Using Systems Biology and Mathematical Modeling Approaches in the Discovery of Therapeutic Targets for Spinal Muscular Atrophy.

Authors:  Matthew E R Butchbach
Journal:  Adv Neurobiol       Date:  2018

7.  Developmental and degenerative cardiac defects in the Taiwanese mouse model of severe spinal muscular atrophy.

Authors:  Gillian K Maxwell; Eva Szunyogova; Hannah K Shorrock; Thomas H Gillingwater; Simon H Parson
Journal:  J Anat       Date:  2018-02-22       Impact factor: 2.610

Review 8.  Cardiac pathology in spinal muscular atrophy: a systematic review.

Authors:  C A Wijngaarde; A C Blank; M Stam; R I Wadman; L H van den Berg; W L van der Pol
Journal:  Orphanet J Rare Dis       Date:  2017-04-11       Impact factor: 4.123

Review 9.  In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy.

Authors:  Kristine S Ojala; Emily J Reedich; Christine J DiDonato; Stephen D Meriney
Journal:  Brain Sci       Date:  2021-02-05

10.  Exercise training reverses skeletal muscle atrophy in an experimental model of VCP disease.

Authors:  Angèle Nalbandian; Christopher Nguyen; Veeral Katheria; Katrina J Llewellyn; Mallikarjun Badadani; Vincent Caiozzo; Virginia E Kimonis
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.